

Concomitant Use of Multiple Nephrotoxins Including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases

Takashi Bando^{a,b}, Masayuki Chuma^{c,d*†}, Hirofumi Hamano^{b,e}, Takahiro Niimura^c, Naoto Okada^a, Masateru Kondo^a, Yuki Izumi^a, Shunsuke Ishida^a, Toshihiko Yoshioka^a, Mizuho Asada^f, Yoshito Zamami^{b,e}, Kenshi Takechi^g, Mitsuhiro Goda^{a,b}, Koji Miyata^b, Kenta Yagi^c, Yuki Izawa-Ishizawa^h, Momoyo Azumaⁱ, Hiroaki Yanagawa^j, Yoshikazu Tasaki^d, and Keisuke Ishizawa^{a,b,c}

Department of ^aPharmacy, ⁱInfection Control and Prevention, ^cClinical Research Center for Developmental Therapeutics, Tokushima University Hospital, Department of ^bClinical Pharmacology and Therapeutics, ^hPharmacology, Tokushima University Graduate School of Biomedical Sciences, Tokushima 770-8503, Japan,

^dDepartment of Hospital Pharmacy and Pharmacology, Asahikawa Medical University, Asahikawa, Hokkaido 078-8510, Japan,

^eDepartment of Pharmacy, Okayama University Hospital, Okayama 700-8558, Japan,

^fDepartment of Medical Molecular Informatics, Meiji Pharmaceutical University, Kiyose, Tokyo 204-8588, Japan,

^gDepartment of Drug Information Analysis, College of Pharmaceutical Sciences, Matsuyama University, Matsuyama 790-8578, Japan,

^jDepartment of Nursing, Faculty of Health and Welfare, Tokushima Bunri University, Tokushima 770-8514, Japan

There is a growing concern about the relationship between vancomycin-associated nephrotoxicity (VAN) and concomitant use of nephrotoxins. We examined this relationship by combined retrospective analyses of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was analyzed for the effects of concomitant use of one or more nephrotoxins on VAN and the types of combinations of nephrotoxins that exacerbate VAN. Next, electronic medical records (EMRs) of patients who received vancomycin (VCM) at Tokushima University Hospital between January 2006 and March 2019 were examined to confirm the FAERS analysis. An elevated reporting odds ratio (ROR) was observed with increases in the number of nephrotoxins administered (VCM + one nephrotoxin, adjusted ROR [95% confidence interval [CI]] 1.67 [1.51-1.85]; VCM + ≥ 2 nephrotoxins, adjusted ROR [95% CI] 1.54 [1.37-1.73]) in FAERS. EMRs analysis showed that the number of nephrotoxins was associated with higher incidences of VAN [odds ratio: 1.99; 95% CI: 1.42-2.78]. Overall, concomitant use of nephrotoxins was associated with an increased incidence of VAN, especially when at least one of those nephrotoxins was a renal hypoperfusion medication (furosemide, non-steroidal anti-inflammatory drugs, and vasopressors). The concomitant use of multiple nephrotoxins, especially including renal hypoperfusion medication, should be avoided to prevent VAN.

Key words: vancomycin-associated nephrotoxicity, polypharmacy, nephrotoxin, spontaneous adverse event reporting database, electronic medical records

Received January 6, 2023; accepted July 3, 2023.

*Corresponding author. Phone: +81-166-69-3482; Fax: +81-166-65-1392
E-mail: chuma-masayuki@asahikawa-med.ac.jp (M. Chuma)

[†]Present affiliation: Department of Hospital Pharmacy and Pharmacology, Asahikawa Medical University, Asahikawa 078-8510, Japan

Conflict of Interest Disclosures: No potential conflict of interest relevant to this article was reported.

Vancomycin (VCM) is a glycopeptide antimicrobial agent used as a first-line intravenous drug for infections caused by methicillin-resistant *Staphylococcus aureus* (MRSA) [1-3]. Vancomycin-associated nephrotoxicity (VAN) is a severe adverse event with an incidence of approximately 5-43% in patients receiving a VCM regimen [1,2,4]. Moreover, the mortality rate associated with VAN has been reported at 15-20% [5,6]. Thus, it is important to prevent VAN by examining its diverse risk factors, including patient-related factors (e.g., age and body weight), VCM-related factors (e.g., dose and concentration), and medication-related factors (e.g., concomitant use of nephrotoxins such as aminoglycosides, furosemide, liposomal amphotericin B, nonsteroidal anti-inflammatory drugs (NSAIDs), piperacillin/tazobactam, vasopressors, and intravenous contrast) [1,3,7,8].

To date, increases in the prevalence of polypharmacy, defined as the prescription of five or more drugs, has led to growing concerns about the consequences of increased nephrotoxin administration [9]. Polypharmacy is a risk factor for acute kidney injury caused by administration of antibiotics [10]. Therefore, it is essential to be cautious about the increased risk of developing VAN with the concomitant use of one or more nephrotoxins. The concomitant use of VCM with renal hypoperfusion medications (e.g., NSAIDs, and diuretics), which are considered nephrotoxins, is associated with an increased risk of kidney injury [11] and VAN [12]. Therefore, it is important to examine the effect of concomitant use of other nephrotoxins, especially in combination with renal hypoperfusion medications, on the development of VAN.

Decisions about VCM therapy in patients with concomitant use of nephrotoxins should be based on data. Recently, real-world data from spontaneous reporting databases and electronic medical records (EMRs) have been extensively used in identifying adverse events related to polypharmacy [13,14]. However, both types of databases have limitations in extracting accurate safety information when analyzed alone [15,16]. The combined analyses of spontaneous reporting databases with other types of real-world databases produces stronger evidence in clinical studies [17-23]. The aim of the present study was to examine the effect of the concomitant use of one or more nephrotoxins in the development of VAN using the combined analysis of two different-type real-world databases.

Materials and Methods

Combined analyses using two databases, the FDA Adverse Events Reporting System (FAERS) and EMRs from a single university hospital, was utilized to examine the association between the occurrence of VAN and concomitant use of multiple nephrotoxins (Fig.1). First, we examined the trends in the number of administered drugs and nephrotoxins stratified by age in the FAERS. Second, we conducted combined analyses of the FAERS and EMR to examine the association between VAN and the concomitant use of nephrotoxins, and to identify the combinations of nephrotoxins that exacerbate VAN. The analysis of EMRs was approved by the Ethics Committee of Tokushima University Hospital (reference number 3,431) and conducted according to the Declaration of Helsinki. The Ethics Committee waived the need for informed consent since this was an observational study using existing data. With respect to the analysis of the FAERS database, institutional review board approval was not required owing to the anonymized nature of the open-access data.

Study population

1. FAERS analysis. Adverse event reports were downloaded from the FDA website <<https://fis.fda.gov/extensions/FPD-QDE-FAERS/FPD-QDE-FAERS.html>>, (accessed 14 April 2020). Data from the first quarter of 2004 to the first quarter of 2020 in the FAERS were analyzed. In the case of duplicate reports, only the most recent report was used for analysis, as recommended by the FDA. Only reports that contained complete age information were extracted. We limited our analysis to patients aged 18 years or older, and those who received VCM intravenously.

2. EMRs analysis. A retrospective case-control study was performed using EMRs from the Tokushima University Hospital in Tokushima, Japan. The inclusion criteria were patients who received VCM between January 2006 and March 2019. The exclusion criteria were patients who (1) received VCM treatment for < 48 h; (2) did not undergo therapeutic drug monitoring (TDM) of VCM; (3) were under 18 years of age; or (4) had prior acute kidney injury (AKI) or renal dysfunction. After exclusion of patients with the above-mentioned criteria and insufficient clinical data, 504 patients were enrolled in this study.




Fig. 1 Flow diagram of the study design.

EMRs, electronic medical records; FAERS, FDA Adverse Events Reporting System; TDM, therapeutic drug monitoring; VCM, vancomycin; VAN, vancomycin-associated nephrotoxicity.

Data collection and definitions

1. FAERS analysis

The description of adverse events conforms to the Medical Dictionary for Regulatory Activities (MedDRA/ver. 23.1) developed by the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Therefore, adverse events were defined using MedDRA-conforming adverse event terminology. VAN was defined by 47 preferred terms in the standardized MedDRA queries under “acute renal failure” (SMQ 20000003) according to a previous report [18]. The only exceptions were “fetal” and “neonatal” as a search term in reports of patients who received VCM (Table 1). Seven drugs or drug types were defined as nephrotoxins previously shown to increase the risk for the occurrence of VAN: aminoglycosides, furosemide, intravenous contrast, liposomal amphotericin B, NSAIDs, piperacillin/tazobactam, and vasopressors [1,7]. Among these, furosemide, NSAIDs, and vasopressors decrease renal blood flow, and were defined as renal hypoperfusion medications [12,24].

2. EMRs analysis

Data on laboratory results and disease history were collected at the initial administration of VCM as the baseline data. We defined VAN as an increase in serum creatinine (SCr) level by ≥ 0.5 mg/dL (44.2 $\mu\text{mol/L}$) or as a 50% or more increase from the baseline SCr level, for ≥ 2 consecutive days from the start to 72 h after VCM administration [5,25]. Nephrotoxins, renal hypoperfusion medications, and other medications in the EMRs were defined according to the criteria described above. In patients without VAN, concomitant use of nephrotoxins was defined as the use of any of the aforementioned nephrotoxins at least from the beginning of administration to 72 h after VCM administration (Fig. 2) [1,5]. In patients with VAN, concomitant use of nephrotoxins was defined as the use of any nephrotoxin from the beginning of VCM administration (or earlier) up to the occurrence of VAN. In patients without VAN, the average VCM trough level during VCM therapy was used for analysis; in patients with VAN, the average VCM trough level before the occurrence of VAN was used for analysis. The average trough level was utilized as an indicator of VCM expo-

Table 1 Forty-seven preferred terms of acute renal failure

Acute kidney injury	Creatinine renal clearance decreased	Intradialytic parenteral nutrition	Renal function test abnormal
Acute phosphate nephropathy	Creatinine urine abnormal	Kidney injury molecule-1	Renal impairment
Albuminuria	Creatinine urine decreased	Nephritis	Renal transplant
Anuria	Crystal nephropathy	Nephropathy toxic	Renal tubular disorder
Azotaemia	Dialysis	Neutrophil gelatinase-associated lipocalin increased	Renal tubular dysfunction
Blood creatinine abnormal	Fractional excretion of sodium	Oedema due to renal disease	Renal tubular injury
Blood creatinine increased	Glomerular filtration rate abnormal	Oliguria	Renal tubular necrosis
Blood urea abnormal	Glomerular filtration rate decreased	Peritoneal dialysis	Subacute kidney injury
Blood urea increased	Haemodialysis	Prerenal failure	Tubulointerstitial nephritis
Blood urea nitrogen/creatinine ratio increased	Haemofiltration	Protein urine present	Urea renal clearance decreased
Continuous haemodiafiltration	Hypercreatininaemia	Proteinuria	Urine output decreased
Creatinine renal clearance abnormal	Hyponatremia	Renal failure	

sure because it is a reasonable risk factor for the development of VAN. Prior AKI in this study was defined by referring to the Kidney Disease: Improving Global Outcome (KDIGO) Clinical Practice Guideline for Acute Kidney Injury, as follows: (1) an increase in SCr level to ≥ 1.5 times that of the baseline level known or presumed to have occurred in the previous 7 days; or (2) an increase in SCr level by ≥ 0.3 mg/dL ($26.5 \mu\text{mol/L}$) within 48 h before or after VCM administration [5,26]. Hypoalbuminemia was defined as an albumin level of < 3.5 g/dL [27]. The estimated glomerular filtration rate (eGFR) was calculated using the following formula: $\text{eGFR (mL/min/1.73 m}^2\text{)} = 194 \times \text{serum creatinine}^{-1.094} \times \text{age}^{-0.287} \times 0.739$ (for females) [28].

Statistical analysis. Differences between two groups were analyzed using either the parametric unpaired *t*-test or non-parametric Mann-Whitney *U* test. Categorical variables were compared using Fisher's exact test or the chi-squared test. Significant differences in categorical variables among three groups were determined using Fisher's exact test followed by Bonferroni multiple comparisons. Multiple logistic regression analysis was used to examine the independent variables posing risk for the development of VAN. In FAERS analysis, signal detection for the risk of adverse events was assessed via a disproportionality analysis using the reported odds ratio (ROR) and 95% confidence interval (CI). A risk signal was considered significant when the ROR and the lower limit of the corresponding 95% CI was > 1 [18,19]. Adjusted ROR was calculated after adjustments for sex and age. The *a priori* selection of variables during EMRs analysis was based on published literature that examined risk factors for the development of VAN; these variables included age, ICU admission, daily dose of VCM, and an average VCM trough level ≥ 20 mg/L [7,25,29]. Candidate factors were selected by considering multicollinearity among those meeting the $p < 0.05$ criteria in a two-group comparison with *a priori* factors. The results of regressions are reported as partial regression coefficients and 95% CIs. *P*-values < 0.05 were considered statistically significant. Data are shown as means (standard deviations) or medians (IQRs). Statistical analysis was performed using JMP[®] 15.0 software (SAS Institute Inc., Cary, NC, USA).




Fig. 3 Proportion of reports by number of administered drugs stratified by age in the FAERS.

A) Proportion of reports by number of administered drugs stratified by age in the FAERS. B) Proportion of reports by number of administered nephrotoxins stratified by age in the FAERS. FAERS, FDA Adverse Events Reporting System.

Table 2 Clinical characteristics in cases with and without VAN in the FAERS

	Without VAN (N = 8573)	With VAN (N = 2772)	P-value
Sex			
Female	3,812 (44.5%)	1,089 (39.3%)	<0.001
Male	4,695 (54.8%)	1,648 (59.5%)	
Unknown	66 (0.8%)	35 (1.3%)	
Age (year)	60.0 (48.0–71.0)	62.0 (51.0–73.0)	<0.001
Number of concomitant nephrotoxins	0 (0–1)	1 (0–2)	<0.001
Number of concomitant agents for renal hypoperfusion	0 (0–1)	0 (0–1)	<0.001

Values for categorical variables are given as count (%) and for continuous variables as median (interquartile range). VAN, vancomycin-associated nephrotoxicity; FAERS, FDA Adverse Events Reporting System.

2. EMRs analysis

Patient characteristics were also compared between the two groups with and without VAN in the EMRs analysis. There were significant differences in sex, daily dose of VCM, the number of concomitant nephrotoxins and concomitant agents for renal hypoperfusion administered, the number of patients with an average VCM trough level ≥ 20 mg/L, and hypoalbuminemia between the two groups ($p < 0.05$) (Table 4). Therefore, these factors were selected as candidates for explanatory

variables in the multivariate analysis while considering multicollinearity. The development of VAN was associated with an average VCM trough level ≥ 20 mg/L (OR, 2.75; 95% CI, 1.62–4.67), hypoalbuminemia (OR, 2.26; 95% CI, 1.04–4.95), and increased the number of concomitant nephrotoxins (OR, 1.99; 95% CI, 1.42–2.78) (Fig. 4). Similarly, the number of renal hypoperfusion agents used concomitantly was associated with the development of VAN (OR, 1.92; 95% CI, 1.19–3.09) when it was used as the explanatory variable instead of

Table 3 Signals of VCM-associated AKI in cases with concomitant nephrotoxins and agents for renal hypoperfusion**A) Signals of VCM-associated AKI in the cases with concomitant nephrotoxins**

	Cases with AKI	Cases without AKI	Crude ROR (95%CI)	Adjusted ROR (95%CI)
VCM	1,074	4,764	1 (Reference)	1 (Reference)
VCM + one nephrotoxin	923	2,460	1.66 (1.50–1.84)	1.67 (1.51–1.85)
VCM + ≥ 2 nephrotoxins	775	1,349	1.53 (1.36–1.72)	1.54 (1.37–1.73)

B) Signals of VCM-associated AKI in cases with concomitant agents for renal hypoperfusion

	Cases with AKI	Cases without AKI	Crude ROR (95% CI)	Adjusted ROR (95% CI)
VCM	1,691	6,398	1 (Reference)	1 (Reference)
VCM + one agent for renal hypoperfusion	675	1,718	1.49 (1.34–1.65)	1.50 (1.36–1.67)
VCM + ≥ 2 agents for renal hypoperfusion	406	457	2.26 (1.93–2.66)	2.26 (1.93–2.66)

ROR in cases with VCM + ≥ 2 Nephrotoxins was calculated as ROR to cases with VCM + one nephrotoxin.
AKI, acute kidney injury; ROR, reporting odds ratio; VCM, vancomycin.

Table 4 Clinical characteristics in patients with and without VAN in EMRs from Tokushima University Hospital

	Without VAN (N = 419)	With VAN (N = 85)	P-value
Sex (Male/Female)	275/144	46/39	0.048
Age (year)	65.8 (55.1–73.8)	63.7 (55.6–69.4)	0.125
ICU admission	55 (13.1%)	17 (20.0%)	0.124
Daily dose of VCM (mg/kg/day)	20.4 (15.1–33.1)	23.2 (17.9–37.8)	0.016
Average VCM trough level (mg/L)	11.0 (7.50–16.0)	17.2 (12.4–24.5)	<0.001
Average VCM trough level ≥ 20 mg/L	69 (16.5%)	35 (41.2%)	<0.001
Length of vancomycin therapy (day)	9.0 (6.0–13.0)	9.0 (6.5–13.0)	0.964
eGFR (mL/min/1.73 m ²)	72.0 (54.2–100.0)	79.1 (57.1–114.3)	0.082
eGFR <60 mL/min/1.73 m ²	61 (17.6%)	24 (15.3%)	0.608
Hypoalbuminemia	334 (79.7%)	76 (89.4%)	0.046
Complication disease			
Hypertension	151 (36.0%)	23 (27.1%)	0.133
Diabetes	165 (39.4%)	24 (28.2%)	0.065
Chronic heart failure	57 (13.6%)	12 (14.1%)	0.864
Chronic kidney disease	24 (5.7%)	4 (4.7%)	1.000
Cancer	258 (61.6%)	49 (57.7%)	0.543
Stroke	22 (5.3%)	6 (7.1%)	0.447
Infection site			
Abdomen	28 (6.7%)	8 (9.4%)	0.359
Bone	10 (2.4%)	1 (1.2%)	0.700
Catheter-related	11 (2.6%)	2 (2.4%)	1.000
Central nervous system	21 (5.0%)	4 (4.7%)	1.000
Respiratory tract	74 (17.7%)	17 (20.0%)	0.643
Urinary tract	16 (3.8%)	2 (2.4%)	0.750
Number of concomitant nephrotoxins	0 (0–1)	1 (0–1)	<0.001
Number of concomitant agents for renal hypoperfusion	0 (0–0)	0 (0–1)	<0.001

eGFR, estimated glomerular filtration rate; ICU, intensive care unit; VAN, vancomycin-associated nephrotoxicity; EMRs, electronic medical records; VCM, vancomycin.




Fig. 4 Analysis of factors influencing the incidence of VAN in the EMRs. EMR, electronic medical records; ICU, intensive care unit; VCM, vancomycin; VAN, vancomycin-associated nephrotoxicity.

the number of nephrotoxins used concomitantly in the multivariate analysis (data not shown).

These results, using combined analyses of FAERS and one hospital's EMR, showed that the number of concomitant nephrotoxins administered was associated with the development of VAN.

Association between VAN and concomitant renal hypoperfusion medication in combined analysis of the FAERS and EMRs. We examined the relationship between concomitant use of renal hypoperfusion medications and the development of VAN stratified by the number of nephrotoxins used concomitantly, based on the above-mentioned FAERS and EMR analysis. FAERS analysis showed that there were significant differences in the reporting rate of VAN between the two groups (with and without renal hypoperfusion medications) when more than two nephrotoxins were used in combination [with renal hypoperfusion medications, 38.6% (687/1780); without renal hypoperfusion medications, 25.6% (88/344); $p < 0.001$] but not in the group with use of a single nephrotoxin [with renal hypoperfusion medications, 26.7% (395/1477), without renal hypoperfusion medications, 27.7% (528/1906); $p = 0.56$] (Fig. 5). EMRs analysis showed that the incidence of VAN in the group which received two or more nephrotoxins including at least one renal hypoperfusion medication was likely to be higher than without renal hypoperfusion medications [with renal hypoperfusion medications; 42.1% (8/19), without renal hypoperfusion medications

18.2% (4/22); $p = 0.17$] (Fig. 5). These results suggest that the risk of development of VAN is increased when multiple nephrotoxin administration includes at least one renal hypoperfusion medication.

Discussion

This study clearly demonstrated a positive association between the number of nephrotoxins and the risk of developing VAN through combined analyses of FAERS and a university hospital EMR. The results suggest that the concomitant use of multiple (≥ 2) nephrotoxins, especially when at least one is a renal hypoperfusion medication is related to an increased risk for VAN. Previous reports studied the association between the increased risk for VAN and concomitant use of each nephrotoxin class, whereas the relationship between the occurrence of VAN, the concomitant use of multiple nephrotoxins, and the combination of nephrotoxins that exacerbate VAN were not examined [1,3,7,8]. The novel findings of the present study provide useful information on the risks of VCM therapy with multiple nephrotoxins in a situation where polypharmacy is becoming more prevalent.

The number of renal hypoperfusion medications such as NSAIDs and diuretics has been shown to be associated with the occurrence of kidney injury [11]. The combination of two hypoperfusion medications with valacyclovir was shown to increase the risk of




Fig. 5 Effect of concomitant use of renal hypoperfusion medications on the incidence of VAN stratified by the number of nephrotoxins including hypoperfusion medications. **A)** Analysis of the FAERS: Reporting rates of VAN were compared between the groups receiving renal hypoperfusion medications and those not receiving them in the group with one nephrotoxin and the group with two or more nephrotoxins, respectively, **B)** EMRs analysis; Incidence of VAN were compared between the groups receiving renal hypoperfusion medications and those not receiving them in the group with one nephrotoxin and the group with two or more nephrotoxins, respectively.

FAERS, FDA Adverse Events Reporting System; EMRs, Electronic medical records; Hypo, renal hypoperfusion medications; Nephro, the number of concomitantly used nephrotoxins; VAN, vancomycin-associated nephrotoxicity.

***: $P < 0.001$; versus the group not receiving renal hypoperfusion medications in cases with two or more nephrotoxins.

developing valacyclovir-associated kidney injury, a well-known drug-induced kidney injury, more than the combination of one such drug with valacyclovir [30]. These results are consistent with the positive association revealed in the present study between the number of administered nephrotoxins and the risk of occurrence of VAN, and suggest that the decision to initiate VCM therapy must be carefully considered in those with concomitant use of multiple nephrotoxins. NSAIDs decrease urinary output via arteriole constriction in the glomerulus [31]. Cisplatin-related nephrotoxicity, which is a common drug-induced kidney injury caused by the injury of proximal tubules, is accelerated by an increase in serum cisplatin concentration due to a decrease in the glomerular filtration rate (GFR) with lower blood pressure [32]. VCM causes nephrotoxicity through proximal tubular injury similar to cisplatin [33,34]. The increased risk for VAN is associated with a decreased GFR from the concomitant use of renal hypoperfusion medications [12]. Diuretics, one of the groups of renal hypoperfusion medications, decrease GFR through hypovolemia, which induces increased VCM trough concentration and is a major risk factor for VAN [35]. Our results also revealed that a high VCM trough concentration poses a risk factor for VAN. Thus,

the concomitant use of renal hypoperfusion medications increase the serum concentration of any other nephrotoxins, suggesting one reason for the positive association between the number of nephrotoxins and the risk for VAN. Furthermore, our analysis of FAERS data showed the association between an increase in the proportion of use of concomitant multiple nephrotoxins and aging. Therefore, it is necessary to carefully monitor for the occurrence of VAN when multiple nephrotoxins are being administered in elderly patients or to hold off using routinely administered nephrotoxins such as furosemide when VCM therapy is deemed necessary. The use of multiple nephrotoxins, especially combinations including renal hypoperfusion medications, should be carefully considered before VCM therapy.

Although the features of the two methodologies complemented each other, there were several limitations inherent to each methodology. First, the category of nephrotoxins was limited to those drugs that have been clearly reported to increase the risk of developing VAN in FAERS- and/or EMR-based studies. Therefore, our results should be generalized carefully in patients receiving combination therapy with other potential nephrotoxins that were not defined as nephrotoxins

herein. Second, the analysis periods of the FAERS and EMR studies were different. This may have affected the overall results. Third, the FAERS data are known to have duplicate reports and significant amounts of missing data. To address this, duplicate reports were removed and only cases with sufficient information were selected. This may affect the results of the FAERS analysis, including the ROR. Fourth, there is no definitive proof of causality between VCM administration and the occurrence of so-called “VAN”. Acute renal failure and its symptoms might have been caused by other unreported determinants. Therefore, the relationship between the occurrence of VAN and an increase in the number of nephrotoxins suggested by the current FAERS analysis should be interpreted with caution. The EMR database is more reliable compared to FAERS and was used in a robust retrospective case-control study design to address some of the limitations of FAERS analysis. The relationship between the occurrence of VAN and increased mortality — as suggested by FAERS analysis — was confirmed using multiple logistic regression analysis while adjusting for the confounding factors. However, this is a retrospective observational study. Due to the limited sample size, our results may not have fully accounted for all clinical factors associated with kidney failure in the context of vancomycin administration. A further study with a larger population concomitantly using multiple nephrotoxins is required to determine which combinations of nephrotoxins worsen VAN because of the limited cases in the present study with concomitant use of each type of nephrotoxin.

In conclusion, combined analyses of the spontaneous reporting database and EMRs from a single university demonstrated the association between the increased number of nephrotoxins and the occurrence of VAN. Our results indicated that the risk for VAN increases when a renal hypoperfusion agent is at least one of multiple nephrotoxins used concomitantly with VCM. The combination of nephrotoxins and VCM should be performed with careful consideration of overall patient safety.

Acknowledgments. This work was supported by JSPS KAKENHI [grant numbers 19K16448 and 20H05798] from the Ministry of Education, Culture, Sports, Science, and Technology of Japan and AMED [grant number 22wm0325037h0002].

References

1. Matsumoto K, Takesue Y, Ohmagari N, Mochizuki T, Mikamo H, Seki M, Takakura S, Tokimatsu I, Takahashi Y, Kasahara K, Okada K, Igarashi M, Kobayashi M, Hamada Y, Kimura M, Nishi Y, Tanigawara Y and Kimura T: Practice guidelines for therapeutic drug monitoring of vancomycin: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. *J Infect Chemother* (2013) 19: 365–380.
2. Matsumoto K, Oda K, Shoji K, Hanai Y, Takahashi Y, Fujii S, Hamada Y, Kimura T, Mayumi T, Ueda T, Nakajima K and Takesue Y: Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring. *Pharmaceutics* (2022) 14: 489.
3. Filippone EJ, Kraft WK and Farber JL: The Nephrotoxicity of Vancomycin. *Clinical pharmacology and therapeutics* (2017) 102: 459–469.
4. Abdelmessih E, Patel N, Vekaria J, Crovetto B, SanFilippo S, Adams C and Brunetti L: Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis. *Pharmacotherapy* (2022) 42: 741–753.
5. Chuma M, Makishima M, Imai T, Tochikura N, Suzuki S, Kuwana T, Sawada N, Komatsu T, Sakaue T, Kikuchi N, Yoshida Y and Kinoshita K: Relationship Between Initial Vancomycin Trough Levels and Early-Onset Vancomycin-Associated Nephrotoxicity in Critically Ill Patients. *Therapeutic drug monitoring* (2018) 40: 109–114.
6. Pan K, Ma L, Xiang Q, Li X, Li H, Zhou Y, Yang L and Cui Y: Vancomycin-associated acute kidney injury: A cross-sectional study from a single center in China. *PLoS one* (2017) 12: e0175688.
7. Kim JY, Yee J, Yoon HY, Han JM and Gwak HS: Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis. *Br J Clin Pharmacol* (2022) 88: 3977–3989.
8. Imai S, Takekuma Y, Kashiwagi H, Miyai T, Kobayashi M, Iseki K and Sugawara M: Validation of the usefulness of artificial neural networks for risk prediction of adverse drug reactions used for individual patients in clinical practice. *PLoS one* (2020) 15: e0236789.
9. Mabuchi T, Hosomi K, Yokoyama S and Takada M: Polypharmacy in elderly patients in Japan: Analysis of Japanese real-world databases. *J Clin Pharm Ther* (2020) 45: 991–996.
10. Nakao S, Hasegawa S, Umetsu R, Shimada K, Mukai R, Tanaka M, Matsumoto K, Yoshida Y, Inoue M, Satake R, Nishibata Y, Liao J and Nakamura M: Pharmacovigilance study of anti-infective-related acute kidney injury using the Japanese adverse drug event report database. *BMC Pharmacol Toxicol* (2021) 22: 47.
11. Lapi F, Azoulay L, Yin H, Nessim SJ and Suissa S: Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. *Bmj* (2013) 346: e8525.
12. Hirai T, Hanada K, Kanno A, Akashi M and Itoh T: Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment. *European journal of clinical pharmacology* (2019) 75: 859–866.
13. Abe J, Umetsu R, Uranishi H, Suzuki H, Nishibata Y, Kato Y, Ueda N, Sasaoka S, Hatahira H, Motooka Y, Masuta M and

- Nakamura M: Analysis of polypharmacy effects in older patients using Japanese Adverse Drug Event Report database. *PLoS one* (2017) 12: e0190102.
14. Liang CK, Chou MY, Hsu YH, Wang YC, Liao MC, Chen MT, Hsiao PY, Chen LK and Lin YT: The association of potentially inappropriate medications, polypharmacy and anticholinergic burden with readmission and emergency room revisit after discharge: A hospital-based retrospective cohort study. *Br J Clin Pharmacol* (2022) 89: 187–200.
 15. Harpaz R, Vilar S, Dumouchel W, Salmasian H, Haerian K, Shah NH, Chase HS and Friedman C: Combing signals from spontaneous reports and electronic health records for detection of adverse drug reactions. *J Am Med Inform Assoc* (2013) 20: 413–419.
 16. Li Y, Ryan PB, Wei Y and Friedman C: A Method to Combine Signals from Spontaneous Reporting Systems and Observational Healthcare Data to Detect Adverse Drug Reactions. *Drug Saf* (2015) 38: 895–908.
 17. Nagashima T, Hayakawa T, Akimoto H, Minagawa K, Takahashi Y and Asai S: Identifying Antidepressants Less Likely to Cause Hyponatremia: Triangulation of Retrospective Cohort, Disproportionality, and Pharmacodynamic Studies. *Clinical pharmacology and therapeutics* (2022) 111: 1258–1267.
 18. Chuma M, Hamano H, Bando T, Kondo M, Okada N, Izumi Y, Ishida S, Yoshioka T, Asada M, Niimura T, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Kasamo S, Izawa-Ishizawa Y, Azuma M, Yanagawa H, Tasaki Y and Ishizawa K: Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes: Combined retrospective analyses of two real-world databases. *Basic Clin Pharmacol Toxicol* (2022) 131: 525–535.
 19. Chuma M, Nakamoto A, Bando T, Niimura T, Kondo Y, Hamano H, Okada N, Asada M, Zamami Y, Takechi K, Goda M, Miyata K, Yagi K, Yoshioka T, Izawa-Ishizawa Y, Yanagawa H, Tasaki Y and Ishizawa K: Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis. *Clinical infectious diseases* (2022) 75: 1416–1422.
 20. Cheng N, Rahman MM, Alatawi Y, Qian J, Peissig PL, Berg RL, Page CD and Hansen RA: Mixed Approach Retrospective Analyses of Suicide and Suicidal Ideation for Brand Compared with Generic Central Nervous System Drugs. *Drug Saf* (2018) 41: 363–376.
 21. Zamami Y, Niimura T, Kawashiri T, Goda M, Naito Y, Fukushima K, Ushio S, Aizawa F, Hamano H, Okada N, Yagi K, Miyata K, Takechi K, Chuma M, Koyama T, Kobayashi D, Shimazoe T, Fujino H, Izawa-Ishizawa Y and Ishizawa K: Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. *Biomed Pharmacother* (2022) 148: 112744.
 22. Goda M, Kanda M, Yoshioka T, Yoshida A, Murai Y, Zamami Y, Aizawa F, Niimura T, Hamano H, Okada N, Yagi K, Chuma M, Izawa-Ishizawa Y and Ishizawa K: Effects of 5-HT₃ receptor antagonists on cisplatin-induced kidney injury. *Clin Transl Sci* (2021) 14: 1906–1916.
 23. Hamano H, Ikeda Y, Goda M, Fukushima K, Kishi S, Chuma M, Yamashita M, Niimura T, Takechi K, Imanishi M, Zamami Y, Horinouchi Y, Izawa-Ishizawa Y, Miyamoto L, Ishizawa K, Fujino H, Tamaki T, Aihara KI and Tsuchiya K: Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. *Kidney international* (2021) 99: 885–899.
 24. Lauschke A, Teichgräber UK, Frei U and Eckardt KU: ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure. *Kidney international* (2006) 69: 1669–1674.
 25. Lodise TP, Patel N, Lomaestro BM, Rodvold KA and Drusano GL: Relationship between initial vancomycin concentration-time profile and nephrotoxicity among hospitalized patients. *Clinical infectious diseases* (2009) 49: 507–514.
 26. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney International Supplements* (2012) 2: 1–138.
 27. Shao M, Wang S and Parameswaran PK: Hypoalbuminemia: a risk factor for acute kidney injury development and progression to chronic kidney disease in critically ill patients. *International urology and nephrology* (2017) 49: 295–302.
 28. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, Yamagata K, Tomino Y, Yokoyama H and Hishida A: Revised equations for estimated GFR from serum creatinine in Japan. *American journal of kidney diseases* (2009) 53: 982–992.
 29. Elyasi S, Khalili H, Dashti-Khavidaki S and Mohammadpour A: Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review. *European journal of clinical pharmacology* (2012) 68: 1243–1255.
 30. Inaba I, Kondo Y, Iwasaki S, Tsuruhashi S, Akaiishi A, Morita K, Oniki K, Saruwatari J, Ishitsuka Y and Irie T: Risk Evaluation for Acute Kidney Injury Induced by the Concomitant Use of Valacyclovir, Analgesics, and Renin-Angiotensin System Inhibitors: The Detection of Signals of Drug-Drug Interactions. *Frontiers in pharmacology* (2019) 10: 874.
 31. Schoolwerth AC, Sica DA, Ballermann BJ and Wilcox CS: Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. *Circulation* (2001) 104: 1985–1991.
 32. Dreischulte T, Morales DR, Bell S and Guthrie B: Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. *Kidney international* (2015) 88: 396–403.
 33. Pais GM, Liu J, Zepcan S, Avedissian SN, Rhodes NJ, Downes KJ, Moorthy GS and Scheetz MH: Vancomycin-Induced Kidney Injury: Animal Models of Toxicodynamics, Mechanisms of Injury, Human Translation, and Potential Strategies for Prevention. *Pharmacotherapy* (2020) 40: 438–454.
 34. Pabla N and Dong Z: Cisplatin nephrotoxicity: mechanisms and renoprotective strategies. *Kidney international* (2008) 73: 994–1007.
 35. Hirai T, Hanada K, Iwamoto T and Itoh T: Involvement of the effect of renal hypoperfusion medications on vancomycin trough concentration: A secondary analysis using a retrospective observational data. *Basic Clin Pharmacol Toxicol* (2021) 129: 376–384.